CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
Public ClinicalTrials.gov record NCT01673672. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Study identification
- NCT ID
- NCT01673672
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Cytos Biotechnology AG
- Industry
- Enrollment
- 365 participants
Conditions and interventions
Conditions
Interventions
- CYT003 Biological
- Placebo Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2012
- Primary completion
- Apr 30, 2014
- Completion
- Apr 30, 2014
- Last update posted
- May 13, 2014
2012 – 2014
United States locations
- U.S. sites
- 21
- U.S. states
- 20
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cytos Investigator Sites | Los Angeles, Huntington Beach, San Jose | California | — | — |
| Cytos Investigator Sites | Walnut Creek, San Diego, Riverside, Fountain Valley | California | — | — |
| Cytos Investigator Sites | Colorado Springs, Denver | Colorado | — | — |
| Cytos Investigator Sites | Waterbury | Connecticut | — | — |
| Cytos Investigator Sites | Miami, Tallahassee | Florida | — | — |
| Cytos Investigator Sites | Albany | Georgia | — | — |
| Cytos Investigator Sites | South Bend | Indiana | — | — |
| Cytos Investigator Sites | Metairie | Louisiana | — | — |
| Cytos Investigator Sites | Bangor | Maine | — | — |
| Cytos Investigator Sites | Bethesda | Maryland | — | — |
| Cytos Investigator Sites | North Dartmouth | Massachusetts | — | — |
| Cytos Investigator Sites | St Louis | Missouri | — | — |
| Cytos Investigator Sites | Ohmaha, Bellevue | Nebraska | — | — |
| Cytos Investigator Sites | Rochester | New York | — | — |
| Cytos Investigator Sites | Cincinnati | Ohio | — | — |
| Cytos Investigator Sites | Oklahoma City | Oklahoma | — | — |
| Cytos Investigator Sites | Eugene, Medford | Oregon | — | — |
| Cytos Investigator Sites | Providence, Warwick | Rhode Island | — | — |
| Cytos Investigator Sites | Spartanburg, Summerville | South Carolina | — | — |
| Cytos Investigator Sites | San Antonio | Texas | — | — |
| Cytos Investigator Sites | Richmond | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01673672, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 13, 2014 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01673672 live on ClinicalTrials.gov.